Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.74 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.74 |
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26668519 | 0.92 | ITGB3 (0.67) | ITGB3ITGA2BACHEROCK2CHRM1 | |
| SCHEMBL2555567 | 0.90 | ITGB3 (0.62) | ITGB3ITGA2BACHECHRM1ALDH1A1 | |
| SCHEMBL8393574 | 0.89 | ACHE (0.69) | ITGB3ITGA2BACHEALDH1A1GAA | |
| SCHEMBL8393679 | 0.86 | ACHE (0.66) | ITGB3ITGA2BACHEALDH1A1GAA | |
| SCHEMBL8391438 | 0.86 | ACHE (0.66) | ITGB3ITGA2BACHEALDH1A1GAA | |
| SCHEMBL7974335 | 0.85 | ITGB3 (0.60) | ITGB3ITGA2BACHEROCK2CHRM1 | |
| SCHEMBL3330915 | 0.84 | SMN1; SMN2 (0.56) | ITGB3ITGA2BCHRM1SMN1; SMN2 | |
| SCHEMBL8395193 | 0.84 | SMN1; SMN2 (0.68) | ITGB3ITGA2BACHEALDH1A1GAA | |
| SCHEMBL8396478 | 0.84 | SMN1; SMN2 (0.68) | ITGB3ITGA2BACHEALDH1A1GAA | |
| SCHEMBL25970123 | 0.82 | ACHE (0.61) | ITGB3ITGA2BACHEALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898631-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | claimed |
| WO-2020126953-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | claimed |
| EP-3898631-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020126953-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| US-9834550-B2 | Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs) | DONG-A ST CO., LTD. (KR) | 2017-12-05 | — | — | US | disclosed |
| US-20160122343-A1 | Novel Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) | DONG-A ST CO., LTD. (KR) | 2016-05-05 | — | — | US | disclosed |
| US-9045453-B2 | Substituted dioxopiperidinyl phthalimide derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8586612-B2 | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| CN-101080388-B | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI AVENTIS DEUTSCHLAND | 2010-12-22 | — | — | CN | disclosed |
| EP-1828131-B1 | PIPERIDINESULFONYLUREAS AND -THIOUREAS, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-06-04 | — | — | EP | disclosed |
| US-20080033016-A1 | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-07 | — | — | US | disclosed |
| CN-101080388-A | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-11-28 | — | — | CN | disclosed |
| EP-1828131-A1 | PIPERIDINESULFONYLUREAS AND -THIOUREAS, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Sanofi-Aventis Deutschland GmbH (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063722-A1 | PIPERIDINESULFONYLUREAS AND -THIOUREAS, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033016-A1 | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | ATP2A1, ATP2A3, ATP2A2 | ITGB3 2530/4885ITGA2B 2715/4885ACHE 1028/4885 |
| US-20160122343-A1 | Novel Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) | KDM1B, KDM1A, KDM3B | ITGB3 4479/4885ITGA2B 4086/4885ACHE 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.